Drug Profile
GSK 3389245A
Alternative Names: ChAd155-RSV; GSK-3389245ALatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Protein vaccines; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 02 Aug 2021 Discontinued - Phase-I for Respiratory syncytial virus infections (Prevention) in United Kingdom (IM) (GlaxoSmithKline pipeline, August 2021)
- 02 Aug 2021 Discontinued - Phase-I/II for Respiratory syncytial virus infections (In infants, Prevention) in Colombia, Finland, Brazil, United Kingdom, Turkey, Thailand and Belgium (IM) (GlaxoSmithKline pipeline, August 2021)
- 02 Aug 2021 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants, Prevention) in Spain, USA, Canada, Italy, Mexico, Panama, Poland, Taiwan (IM) (GlaxoSmithKline pipeline, August 2021)